MONTREAL, June 9, 2005 (PRIMEZONE) -- Viropro Pharma Inc., a subsidiary of Viropro, Inc. (OTCBB:VPRO), today announced the appointment of Ms. Kawtar Sounni to the position Director -- Business Development North Africa. Based in Morocco, Ms. Sounni will oversee all business activities related to the development of products and technologies in North Africa with a particular focus on Morocco.
Her appointment provides Viropro Pharma with a highly-favored gateway into all African countries. Dr. Jean Marie Dupuy, President of Viropro Pharma declared: "The huge business potential offered by Morocco and its neighboring countries has pushed Viropro Pharma to have a permanent presence in Morocco in order to develop and sustain growth of our business in the area of biopharmaceuticals and nutraceuticals."
Ms. Sounni brings to Viropro Pharma over 10 years experience in strategic development in North Africa for well-known North American companies such as ACT (now Dassault System Canada), Matol, TechnoPos, Laboratoires SM, Galaxia Canada, P&G, Colgate Palmolive and Novartis. Ms. Sounni has executed high-profile negotiation contracts and developed strategic business implantations when acting as Vice-president -- Development for Technopos.
With her impressive portfolio of private and institutional contacts, Ms. Kawtar Sounni will provide Viropro Pharma with critical expertise in the implementation of strategies aimed at successful penetration of the Moroccan market. Dr. Dupuy, President of Viropro Pharma added: "We are very proud to welcome Ms. Sounni amongst our team and I am convinced that her expertise on the North African market and her large network of high flying contacts will favor a quick implantation of Viropro Pharma in this part of the world."
About Viropro, Inc.
Viropro, Inc. (OTCBB:VPRO) is establishing a growth portfolio in Life Sciences markets through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
Viropro, Inc's Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements". Forward looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.